Cargando…

α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis

BACKGROUND AND AIMS: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filip, Rafał, Goliat, Błażej, Dziechciaż, Małgorzata, Dąbrowski, Piotr, Osuchowski, Michał, Paluszkiewicz, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501135/ https://www.ncbi.nlm.nih.gov/pubmed/31143480 http://dx.doi.org/10.1155/2019/2091089

Ejemplares similares

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
por: Terui, Hitoshi, et al.
Publicado: (2023)

Evaluation of the Developmental Toxicity of Vedolizumab, an α(4)β(7) Receptor Antagonist, in Rabbit and Nonhuman Primate
por: Crawford, David, et al.
Publicado: (2019)

Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis
por: Shalabi, Doaa, et al.
Publicado: (2019)

Circulating exosomes express α(4)β(7) integrin and compete with CD4+ T cells for the binding to Vedolizumab
por: Domenis, Rossana, et al.
Publicado: (2020)

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis
por: Besendorf, Laura, et al.
Publicado: (2022)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Regional Ileitis
por: Jeffrey, James S.
Publicado: (1949)

Regional Ileitis
por: Kaikini, V. M.
Publicado: (1938)

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
por: Schneider, Anna-Maria, et al.
Publicado: (2018)

Use of vedolizumab in a patient with chronic and refractory pouchitis
por: Orfanoudaki, Eleni, et al.
Publicado: (2018)

Ileitis: A Case
por: Breed, S. P.
Publicado: (1869)

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease
por: Singh, Harmanjit, et al.
Publicado: (2016)

Crohn's ileitis and salpingo-oophoritis.
por: Allen, D. C., et al.
Publicado: (1995)

Regional Ileitis (Crohn's Disease)
Publicado: (1943)

Capecitabine-induced terminal ileitis
por: Al-Gahmi, Aboelkhair Mohammad, et al.
Publicado: (2012)

Capecitabine-Associated Terminal Ileitis
por: van Hellemond, Irene E.G., et al.
Publicado: (2018)

Management of Asymptomatic Terminal Ileitis
por: Donet, Jean A, et al.
Publicado: (2020)

Understanding the Presentation of Terminal Ileitis
por: Jain, Ashali, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
por: Kaneoka, Ayaka, et al.
Publicado: (2022)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Intestinal-Specific TNFα Overexpression Induces Crohn’s-Like Ileitis in Mice
por: Bamias, Giorgos, et al.
Publicado: (2013)

Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
por: Diana, Pietro, et al.
Publicado: (2018)

Terminal ileitis is not always Crohn’s disease
por: Bojic, Daniela, et al.
Publicado: (2011)

Ileitis Secondary to Oral Capecitabine Treatment?
por: Radwan, Rami, et al.
Publicado: (2012)

Radiation Ileitis Leading to Enterovesical Fistula
por: Hokama, Akira, et al.
Publicado: (2022)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Role of integrin expression in the prediction of response to vedolizumab: A prospective real‐life multicentre cohort study
por: De Galan, Cara, et al.
Publicado: (2022)

Eosinophilic ascites due to severe eosinophilic ileitis
por: Setia, Namrata, et al.
Publicado: (2010)

Paneth cell α-defensin misfolding correlates with dysbiosis and ileitis in Crohn’s disease model mice
por: Shimizu, Yu, et al.
Publicado: (2020)

Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
por: Nakamura, Masanao, et al.
Publicado: (2020)

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Facing Terminal Ileitis: Going Beyond Crohn’s Disease
por: Goulart, Ricardo de Alvares, et al.
Publicado: (2016)

Visceral pain triggered by traction on the ileocecal ligament with ileitis
por: Janyaro, Habibullah, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_svk7ssn0u4qn9sgvrhia4j1lhk